Abstract
We have investigated the effect of subchronic exposure to tetradifon (TDF), as an endocrine disruptor chemical, on some parameters related to serious metabolomic disorders such as obesity, type 2 diabetes and hyperlipidemia. TDF promoted significant increases in both duodenal and pancreatic alpha-amylase and lipase especially in the 12-weeks treated rats. Plasmatic glucose and lipid profile; total cholesterol (T-cholesterol), low density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c) and glyceride, were markedly disrupted. Compared with controls, biochemical liver injury parameters: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and lactate dehydrogenase (LDH) were significantly increased. Moreover, notable pathological features were reported in liver tissues. These results confirm a strong relationship between exposure to an endocrine disruptor and metabolic disorders. In fact, subchronic exposure to TDF lead to lipidemic and glycemic disruption associated hyperactivity in both alpha-amylase and lipase. Overall, these disruptions could be an important step on the pathway to metabolic pathology.